HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer
Open Access
- 16 August 2022
- journal article
- research article
- Published by Elsevier in EBioMedicine
- Vol. 83, 104205
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Molecular Profiling of Aromatase Inhibitor–Treated Postmenopausal Breast Tumors Identifies Immune-Related Correlates of ResistanceClinical Cancer Research, 2013
- Comprehensive molecular portraits of human breast tumoursNature, 2012
- Deconstructing the molecular portraits of breast cancerMolecular Oncology, 2010
- Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancerBreast Cancer Research, 2010
- p53 mutation, deprivation and poor prognosis in primary breast cancerBritish Journal of Cancer, 2010
- The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2Nature Clinical Practice Oncology, 2008
- Proliferation and Apoptosis as Markers of Benefit in Neoadjuvant Endocrine Therapy of Breast CancerClinical Cancer Research, 2006
- Biomarker Changes During Neoadjuvant Anastrozole, Tamoxifen, or the Combination: Influence of Hormonal Status and HER-2 in Breast Cancer—A Study from the IMPACT TrialistsJournal of Clinical Oncology, 2005
- Significance analysis of microarrays applied to the ionizing radiation responseProceedings of the National Academy of Sciences, 2001
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neuOncogeneScience, 1987